DUBLIN–(BUSINESS WIRE)–Research and Markets has announced the addition of the “Novel Drugs and Devices to Lower Intraocular Pressure, 2016 – 2026” report to their offering. An imbalance in the production and / or drainage of aqueous humor within the …
Visioneering Technologies, Inc. Announces Tony Sommer as New SVP, Sales & Marketing
ALPHARETTA, Ga.–(BUSINESS WIRE)–Visioneering Technologies names Tony Sommer senior VP of Sales and Marketing. Sommer will direct planning, development and execution of growth plans for the NaturalVue® contact lens portfolio.
Aerie Pharmaceuticals Raises $125 Million in Public Offerings
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases…
Researchers identify and treat new variant of antibiotic-resistant E. coli
Researchers at Massachusetts Eye and Ear have discovered a new mutation in a highly antibiotic-resistant strain of E. coli that resists clearance by the body’s own immune system by inhibiting white blood cells that ordinarily kill and remove bacteria.
Aerie Pharmaceuticals Announces Public Offering of Common Stock
IRVINE, Calif.–(BUSINESS WIRE)–Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage pharmaceutical company focused on the discovery, development and commercialization of first-in-class therapies for the treatment of glaucoma and other diseases of the eye, today announced that it has commenced a registered underwritten public offering of $50 million of shares of its common stock. Cantor Fitzgerald & Co. is acting as the sole underwriter for the offering. Aerie intends to use the net
VIDEO: Post hoc analysis of DRCR.net Protocol I
COPENHAGEN — At the Euretina meeting, Albert Augustin, MD, reports on the post hoc analysis of DRCR.net Protocol I data, evaluating ranibizumab against triamcinolone in patients with diabetic macular edema.